10-Q quarterly report · filed Nov 9, 2026

ArriVent BioPharma, Inc. (AVBP) Q3 2026 10-Q Quarterly Report

Short answer

ArriVent BioPharma, Inc. (AVBP) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $5M with net income of −$40M.

Q3 2026 key financials · XBRL

Revenue
$5M
Net income
−$40M
−15.3% YoY · +19.2% QoQ
Operating margin
-867.5%
EPS (diluted)
−$0.81
−6.6% YoY · +22.9% QoQ

Source: XBRL data from the ArriVent BioPharma, Inc. (AVBP) Q3 2026 10-Q on SEC EDGAR. USD.

ArriVent BioPharma, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Collaboration revenue $5.0M, versus $0 in Q3 2025, from ARR-002 upfront payment
  • Operating loss $43.4M vs $38.3M YoY, net loss $40.3M vs $35.0M
  • R&D expense $38.9M vs $32.2M, early-stage programs increased $5.1M
  • Cash, equivalents and short-term investments $393.2M; operating cash used $122.2M
  • FURVENT failed its primary endpoint; existing liquidity expected to fund operations through at least twelve months

Risk Factors

  • USPTO ex parte reexamination of RE ’687 Patent, initiated July 2026, could narrow or cancel claims
  • RE ’687 Patent prosecution closed October 19, 2026, with certificate intended to confirm claims
  • Patent validity disputes could eliminate protection for current and future product candidates
  • Patent litigation could divert management and scientific resources and increase defense costs

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other ArriVent BioPharma, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.